Table 1 Baseline characteristics of the patients
Characteristic | Number of patients (%) n = 91 |
|---|---|
Gender | |
Female | 78 (85.7%) |
Male | 13 (14.3%) |
Range of age | |
0–20 | 2 (2.2%) |
21–30 | 14 (15.4%) |
31–40 | 27 (29.7%) |
41–65 | 48 (52.7%) |
Ethnicity | |
Middle East | 45 (49.4%) |
Asian | 17 (18.7%) |
Europe | 20 (22.0%) |
Rest of the world | 9 (9.9%) |
Previous years of migraine | |
0–19 years | 31 (34.1%) |
≥20 years | 60 (65.9%) |
Type of migraine | |
Medication overuse headache | 14 (15.4%) |
Episodic migraine | 33 (36.3%) |
Chronic migraine | 44 (48.3%) |
Reduction of migraine days in all migraine types | |
0–24% | 13 (14.3%) |
25–49% | 5 (5.5%) |
50–74% | 10 (11.0%) |
75–100% | 63 (69.2%) |
Dose increase of erenumab to 140 mg | |
Yes | 14 (15.4%) |
No | 77 (84.6%) |